Itm Solucin Gmbh
Clinical trials sponsored by Itm Solucin Gmbh, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Radioactive drug aims to shrink Hard-to-Treat gut tumors Results expected Jun 2027 (estimated)
-
New hope for kids with tough cancers: targeted radiation trial launches
Disease control Recruiting nowThis early-stage trial tests a radioactive drug (Lu-177 edotreotide) in children aged 2 to 17 with cancers that have a specific marker (SSTR-positive). The goal is to find the right dose and check safety. About 20 children whose cancer has returned or not responded to prior treat…
Phase 1 • Sponsor: ITM Solucin GmbH • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Early access program offers investigational meningioma treatment
Disease control Expanded accessThis program gives eligible patients with meningioma access to the investigational drug ITM-11 before it is officially approved. The treating doctor decides if the possible benefits outweigh the risks. The program is only available in certain countries.
Sponsor: ITM Solucin GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC